Pluri partners with ZEO ScientifiX to commercialize regenerative medicine products in US
PLUR•Pluri entered a partnership agreement with ZEO ScientifiX on October 26, 2026, to license Pluri’s regenerative medicine portfolio. ZEO will receive exclusive US commercialization rights at closing, while the transactions will give Pluri 50% of ZEO’s outstanding shares, with additional warrants and equity provisions.
1. Partnership terms
Pluri entered a partnership agreement with ZEO ScientifiX on October 26, 2026, to license its regenerative medicine portfolio. At closing, ZEO will receive exclusive US commercialization rights, with potential expansion to Latin America. The transactions will give Pluri 50% of ZEO’s outstanding shares; royalties increase as Pluri’s equity ownership declines. Five-year warrants allow Pluri to buy an additional 5% stake at $4 per share and 2.5% at $5.50 per share, and another 5% stake becomes payable if ZEO’s volume-weighted average closing share price reaches $5.50 over 10 trading days.
